Guidance on JAK inhibitor treatment for inborn errors of JAK-STAT signaling, 2026: International consensus statement on behalf of the European Society for Immunodeficiencies/European Society for Blood and Marrow Transplantation–Inborn Errors Working Party and ERN-RITA
Journal of Allergy and Clinical Immunology · 2026-08 · 158 (2) · 598-609.e5
DOI: 10.1016/j.jaci.2026.05.005 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Allergy and Clinical Immunology, 2026-08. Verfasst von Peter Olbrich und 47 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Biomedicina de Sevilla, Research Group "Inborn Errors of Immunity," Pediatric Infectious Diseases, Rheumatology and Immunology Unit, IBi…. Hauptthemen laut MEDLINE: Janus Kinase Inhibitors, Janus Kinases, STAT Transcription Factors, Immunologic Deficiency Syndromes. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 108 Literaturangaben. Gefördert von: Research and Innovative Technology Administration.
Abstract (Originalsprache)
BACKGROUND: Inborn errors of immunity (IEI) associated with gain of function (GOF) in the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathways (JAK-STAT-GOF IEI) are rare disorders characterized by immune dysregulation, autoimmunity, malignancy, and increased infection susceptibility. To date, no JAK inhibitors (JAKi) are licensed for these conditions, but they are frequently prescribed off-label, even though high-quality evidence and treatment guidelines remain limited. OBJECTIVE: We developed evidence- and consensus-based recommendations for JAKi treatment in JAK-STAT-GOF IEI across all age groups on the basis of a systematic literature review and expert consensus. METHODS: An international expert group conducted a systematic literature review and developed recommendations on JAKi treatment in JAK-STAT-GOF IEI using a modified Delphi approach. Recommendations were developed based on published evidence, data from an international retrospective cohort study, and patient representative input. These statements were then tested for consensus in a 2-round Delphi survey procedure in a larger, interdisciplinary expert panel. RESULTS: Consensus- and evidence-based guidance is presented across 5 thematic areas: (1) JAKi indications/contraindications, (2) pretreatment assessment, (3) pharmacology/dosing, (4) monitoring, and (5) use in the context of hematopoietic stem cell transplantation. A total of 51 statements were established and contextualized with the available evidence. CONCLUSION: This consensus provides structured guidance for clinicians managing JAK-STAT-GOF IEI with JAKi. While prospective trials will further refine these strategies, this guidance represents the current international standard of care, reflecting the synthesis of clinical experience and the best available evidence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Instituto de Biomedicina de Sevilla, Research Group "Inborn Errors of Immunity," Pediatric Infectious Diseases, Rheumatology and Immunology Unit, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla,…
- Department of Allergology and Clinical Immunology, Children's Hospital of Eastern Switzerland, Sankt Gallen, Switzerland; Department of Quantitative Biomedicine, Center for Human Immunology, University of Zurich, Zurich…
- Institut de Recerca Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain; Clinical Immunology Unit Hospital, Sant Joan de Déu-Hospital Clínic de Barcelona, Barcelona, Spain.
- Biblioteca Médica, Hospital Universitario de Getafe, Madrid, Spain.
- Department of Internal Medicine, Sorbonne University, Assistance Publique Hôpitaux de Paris, Saint-Antoine Hospital, Paris; Laboratory of Immunogenetics of Pediatric Autoimmune Diseases, Institut National de la Santé et…
- Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital, Houston, Tex; Department of Pediatrics, Baylor College of Medicine, Immunology/Allergy/Retrovirology, Texas Children's Hospital, Houston,…
Förderung
- Research and Innovative Technology Administration
Zitieren
APA
Olbrich, P., Fischer, M., Deyà-Martinez, Á., Campos-Asensio, C., Neth, O., Hadjadj, J., Forbes Satter, L. R., Leiding, J. W., Torgerson, T. R., Bakhtiar, S., Baris, S., Badolato, R., Bloomfield, M., Buddingh, E. P., Burroughs, L. M., Burns, S., Cooper, M. A., Crickx, E., Ehl, S., …, & Inborn Errors Working Party of ESID/EBMT and ERN-RITA (2026). Guidance on JAK inhibitor treatment for inborn errors of JAK-STAT signaling, 2026: International consensus statement on behalf of the European Society for Immunodeficiencies/European Society for Blood and Marrow Transplantation–Inborn Errors Working Party and ERN-RITA. Journal of Allergy and Clinical Immunology, 158(2), 598-609.e5. https://doi.org/10.1016/j.jaci.2026.05.005
Vancouver
Olbrich P, Fischer M, Deyà-Martinez Á, Campos-Asensio C, Neth O, Hadjadj J, et al. Guidance on JAK inhibitor treatment for inborn errors of JAK-STAT signaling, 2026: International consensus statement on behalf of the European Society for Immunodeficiencies/European Society for Blood and Marrow Transplantation–Inborn Errors Working Party and ERN-RITA. Journal of Allergy and Clinical Immunology. 2026;158(2):598-609.e5. doi:10.1016/j.jaci.2026.05.005
BibTeX
@article{Olbrich2026,
author = {Olbrich, Peter and Fischer, Marco and Deyà-Martinez, Ángela and Campos-Asensio, Concepción and Neth, Olaf and Hadjadj, Jérôme and Forbes Satter, Lisa R and Leiding, Jennifer W and Torgerson, Troy R and Bakhtiar, Shahrzad and Baris, Safa and Badolato, Raffaele and Bloomfield, Markéta and Buddingh, Emilie Pauline and Burroughs, Lauri M and Burns, Siobhan and Cooper, Megan A and Crickx, Etienne and Ehl, Stephan and Farmand, Susan and Freeman, Alexandra F and González-Granado, Luis Ignacio and Hagin, David and Hanitsch, Leif Gunnar and Hanzlikova, Jana and Hauck, Fabian and Ivorra-Cortés, José and Körholz, Julia and Lankester, Arjan C and Leahy, Timothy Ronan and Meyts, Isabelle and Milner, Joshua D and Nademi, Zohreh and Pachlopnik-Schmid, Jana and Pergent, Martine and Prévot, Johan and Rivière, Jacques and Roxo-Junior, Persio and Schütz, Catharina and Slatter, Mary A and Soler-Palacin, Pere and Warnatz, Klaus and Vítovcová, Petra and Vaastert, Sebastian J and Neven, Bénédicte and Albert, Michael H and Speckmann, Carsten and Inborn Errors Working Party of ESID/EBMT and ERN-RITA, Inborn Errors Working Party of ESID/EBMT and ERN-RITA},
title = {Guidance on JAK inhibitor treatment for inborn errors of JAK-STAT signaling, 2026: International consensus statement on behalf of the European Society for Immunodeficiencies/European Society for Blood and Marrow Transplantation–Inborn Errors Working Party and ERN-RITA},
journal = {Journal of Allergy and Clinical Immunology},
year = {2026},
volume = {158},
number = {2},
pages = {598--609.e5},
doi = {10.1016/j.jaci.2026.05.005}
}
EUVIMED